WHO ICTRP trial
Effect of aspirin and simvastatin in schizophrenia
IRCT20210110049994N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20210110049994N1 |
|---|---|
| Public title | Effect of aspirin and simvastatin in schizophrenia |
| Scientific title | Comparison of aspirin and simvastatin efficacy as adjuvant treatment on negative and positive symptoms and general psychopathology in patient with schizophrenia |
| Primary sponsor | University of social welfare and rehabilitation sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Countries | Iran (Islamic Republic of) |
| Conditions | schizophrenia. Schizophrenia |
| Interventions | Intervention 1: Intervention group: patients with schizophrenia that were treated by risperidone to whom 650 mg of aspirin (325 mg twice daily) will be added daily. Intervention 2: Intervention group: patients with schizophrenia that were… |
| Registration date | Feb 5, 2021 |
| Target size | 45 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: